A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Histologically or cytologically confirmed metastatic or unresectable solid tumor.
Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator.
Have progressed on or after all prior standard-of-care therapies for metastatic disease.
Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
KEAP1 nonsense mutation (any position)
KEAP1 frameshift mutation (any position)
Any unresolved toxicity Grade ≥2 per CTCAE version 5.0 from previous anticancer treatment.
Current or prior treatment with anti-epileptic medications for the treatment or prophylaxis of seizures.
7
Treatment groupsSee each treatment group below.